Predictors of response to infliximab in paediatric perianal Crohn's disease

Dupont-Lucas, Claire; Dabadie, A.; Alberti, Corinne; Ruemmele, Frank M

doi:10.1111/apt.12928

Cited by 29 publications

(28 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[22][23][24] IFX is recommended as an induction and maintenance treatment for CD patients with PD, 25 and Dupont-Lucas et al reported that 75% of older pediatric patients responded well to IFX treatment, and their PD had improved by 1 year. 26 Four of five patients with NUC-PD responded to IFX with a significant improvement in perianal disease. However, despite the response to IFX, severely destructive perianal lesions may eventually require ostomy placement for the early loss of response or sphincter destruction.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Infliximab for very early‐onset inflammatory bowel disease: A tertiary center experience in Japan

Takeuchi

Kaburaki

Arai

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Very early‐onset inflammatory bowel disease (VEO‐IBD), defined as IBD diagnosed before 6 years of age, tends to be refractory to conventional treatment for IBD. However, there have been a few reports about the usage of infliximab for VEO‐IBD. This study aimed to evaluate the efficacy and safety of infliximab for VEO‐IBD. Methods Medical records of a cohort of children with VEO‐IBD who had received infliximab in a Japanese tertiary children's hospital were retrospectively reviewed for their disease characteristics and clinical course. Subjects were categorized into three groups for the descriptive comparison: ulcerative colitis type (UCT), non‐UCT with perianal disease (NUC‐PD), and non‐UCT without perianal disease (NUC‐NPD). Results Seventeen VEO‐IBD patients (five UCT, five NUC‐PD, and seven NUC‐NPD) had received infliximab as their first biologic. In the UCT group, infliximab was continued over 54 weeks in two patients, and three eventually required surgery. In contrast, all patients in the NUC‐PD and NUC‐NPD groups followed up over 54 weeks remained on infliximab, and two of three patients and three of five patients were in remission at week 54, respectively. Infusion reactions occurred in all five UCT, three of five NUC‐PD, and two of seven NUC‐NPD patients; however, except for two patients with severe reactions, infliximab was continued with premedication and slow infusions. Conclusions Infliximab appeared useful for children with VEO‐IBD. Children with NUC‐PD and NUC‐NPD responded better with less infusion reaction compared with that with UCT.

show abstract

Section: Discussionmentioning

confidence: 91%

“…IFX is recommended as an induction and maintenance treatment for CD patients with PD, and Dupont‐Lucas et al . reported that 75% of older pediatric patients responded well to IFX treatment, and their PD had improved by 1 year . Four of five patients with NUC‐PD responded to IFX with a significant improvement in perianal disease.…”

Section: Discussionmentioning

confidence: 99%

Infliximab for very early‐onset inflammatory bowel disease: A tertiary center experience in Japan

Takeuchi

Kaburaki

Arai

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Maintenance Of Remissionmentioning

confidence: 97%

Management of Crohn's disease

et al. 2015

View full text Add to dashboard Cite

Crohn's disease (CD) is rapidly increasing in children so an up to date knowledge of diagnosis, investigation and management is essential. Exclusive enteral nutrition is the first line treatment for active disease. The vast majority of children will need immunosuppressant treatment and around 20% will need treatment with biologics. Recent guidelines have helped make best use of available therapies.

show abstract

“…40 41 Infliximab improved outcomes of perianal CD with response rates of 75% and remission rates of 50% at 1 year. 42 Adalimumab achieved 1-year remission rates of 45% in anti-TNFα antibody naïve children and 20% in infliximab non-responders. 43 Infliximab is first administered intravenously in doses of 5 mg/kg at weeks zero, two and six followed by 8-weekly infusions.…”

Section: Anti-tnfα Antibodiesmentioning

confidence: 97%

Management of Crohn's Disease

Greig¹

2013

View full text Add to dashboard Cite

Predictors of response to infliximab in paediatric perianal Crohn's disease

Abstract: SUMMARY BackgroundIt is reported that 27-54% of paediatric patients with perianal Crohn's disease (CD) do not respond to infliximab (IFX).

Cited by 29 publications

References 32 publications

Infliximab for very early‐onset inflammatory bowel disease: A tertiary center experience in Japan

Infliximab for very early‐onset inflammatory bowel disease: A tertiary center experience in Japan

Management of Crohn's disease

Management of Crohn's Disease

Contact Info

Product

Resources

About